RT Journal Article
SR Electronic
T1 15-Deoxy-Δ12,14-prostaglandin J2Induces G1 Arrest and Differentiation Marker Expression in Vascular Smooth Muscle Cells
JF Molecular Pharmacology
JO Mol Pharmacol
FD American Society for Pharmacology and Experimental Therapeutics
SP 837
OP 844
DO 10.1124/mol.58.4.837
VO 58
IS 4
A1 Yoshikazu Miwa
A1 Toshiyuki Sasaguri
A1 Hiroyasu Inoue
A1 Yoji Taba
A1 Akio Ishida
A1 Takeo Abumiya
YR 2000
UL http://molpharm.aspetjournals.org/content/58/4/837.abstract
AB In search of substances useful for the treatment of atherosclerotic vascular diseases, we studied the effects of 15-deoxy-Δ12,14-prostaglandin J2(15d-PGJ2), a natural ligand for peroxisome proliferator-activated receptor γ, on the proliferation and differentiation of vascular smooth muscle cells (VSMCs). 15d-PGJ2 but not WY14643, an agonist for peroxisome proliferator-activated receptor α, dose-dependently inhibited VSMC proliferation; the effect was maximal at 12 μM. This compound strongly suppressed the activities of cyclin-dependent kinases (Cdk) 4, 6, and 2, thereby preventing the phosphorylation of the retinoblastoma protein. These Cdks seemed to be inhibited through two mechanisms: the down-regulation of cyclin D1 and the up-regulation of Cdk inhibitor p21Cip1/Waf1/Sdi1. 15d-PGJ2was found to inhibit the phosphatidylinositol 3-kinase/protein kinase B signaling pathway, which mediates cyclin D1 expression. Mitogenic stimulation of quiescent cells decreased the level of mRNA for the smooth muscle-specific myosin heavy-chain SM1, whereas this reduction was prevented by 15d-PGJ2. A long-term treatment of exponentially growing VSMCs with 15d-PGJ2 markedly elevated the mRNA level of SM1 and, moreover, induced SM2, another isoform expressed exclusively in mature VSMCs. 15d-PGJ2 also increased the expression levels of calponin-h1 and smooth muscle α-actin. These results suggest that 15d-PGJ2 induces G1 arrest by two distinct mechanisms and promotes VSMC differentiation.